FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: 'Business as Usual' for China Drugmakers Despite Scrutiny of Cross-Border Tech Deals, JW Therapeutics CEO Says

By

The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) Therapeutics (HKG:2126) CEO Leo Tian.

"For us, everything is business as ​usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly ⁠dependent on international cooperation," Reuters quoted Tian as saying.

JW is "actively seeking cooperation" with companies outside China for assets in its pipeline, the report said, citing Tian.

Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.

Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Tokyo Kiraboshi Financial Group to Receive 8 Billion Yen Dividend from Subsidiary for UI Bank Capital Increase

Tokyo Kiraboshi Financial Group (TYO:7173) will receive a dividend of 8 billion yen from its consolidated subsidiary, Kiraboshi Bank, on June 1, to help fund a capital increase of UI Bank.The dividend will be recorded as operating income in the company's non-consolidated financial statements for the fiscal year ending March 31, 2027, according to a Tokyo bourse filing on Wednesday.However, because the dividend originates from a consolidated subsidiary, it will have no impact on the Group's consolidated financial results for the same period.The disclosure was made as the event requires submission of an extraordinary report under Japan's Financial Instruments and Exchange Act.

$TYO:7173
Asia

SGSG's Delisting Risk Lifted

SGSG Science & Technology's (SHE:300561) delisting risk was lifted on Wednesday, according to a same-dated filing on the Shenzhen bourse.The software developer received a delisting warning in April 2025 after reporting negative earnings in its 2024 report and failing to execute controls over sales operations.The Shenzhen Stock Exchange approved the company's application to remove the delisting risk after the company underwent rectification in their internal controls.Trading of SGSG's shares were temporarily suspended.

$SHE:300561
Asia

ICICI Securities Upgrades Nazara Technologies to Add from Hold; Price Target is INR330

Nazara Technologies (BOM:543280, NSE:NAZARA) has an average rating of overweight and mean price target of 310 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BOM:543280$NSE:NAZARA